The identification of resistance mechanisms associated with the PIK3CA H1047R mutation and the definition of crosstalk existing between the MAPK and PI3K–Akt pathways demonstrated in this study further encourage the adoption of combined treatments with both MAPK- and PI3K–Akt-selective inhibitors that are useful for sensitizing melanoma cells to therapy. The gene discussed is PIK3CA; the disease is melanoma.